Is the Breakout On in Kali Inc
(OTCMKTS:
KALY)?
April 8, 2019 -- InvestorsHub NewsWire -- By James Hudson
If you’re looking for a basing pattern that has recently bent
itself around toward a bullish breakout, then you would probably be
happy to stumble across the Kali Inc (OTCMKTS:
KALY) chart. Shares of the stock have been
tracing sideways with very definite support at the one penny level
for most of 2019. That action was followed up last week by a clear
breakout above its multi-month range highs. To further flesh out
the story, the company just announced plans to reveal a fourth
research and development initiative for a treatment of a heath
issue with a cannabis extract derived from the company’s patented
cannabis extraction process.
According to the release, “the company currently has ongoing
cannabis extract research and development targeting four specific
health issues, COPD, Type 2 Diabetes, Cancer Pain Management and
one additional health issue KALY plans to announce next week
leading up to an online presentation with more detail on each of
the treatment developments later this month. The market for Type 2
Diabetes is expected to be a $64 billion market by 2026. The market
for COPD treatment is anticipated to reach $14 billion by 2025. The
overall pain management treatment market is anticipated to reach
$83 billion by 2024. Beyond the four specific cannabis therapies
currently in various stages of research and development, KALY has a
number of additional target therapies in its research
pipeline.”
Kali Inc (OTCMKTS:
KALY) trumpets itself as a developer and owner of a patented
cannabis extraction process – U.S. Patent No. 9,199,960 entitled
“METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS
INCLUDING THE CANNABIS PLANT.”
This came about on November 15, 2018, with the acquisition of
NCM Biotech.
With the patented intellectual property (IP), to include the
existing and ongoing research and development acquired from NCM
Biotech, Kali now focuses on the development of pharmaceuticals to
treat various illnesses, diseases and chronic pain as a symptom of
various diagnoses. Kali also concentrates on the development of
health and wellness therapies.
NCM Biotech (acquired by Kali-Extracts) in collaboration with
Beech Tree Labs, Inc. (BTL) of Providence, Rhode Island, conducted
a series of in vitro genomic experiments to evaluate the potential
of cannabis extracts derived from KALY’s patented extraction
process in the treatment of respiratory diseases. The
experiments were designed to evaluate pure cannabis extracts and
cannabis extracts in combination with other therapies in the
treatment of chronic obstructive pulmonary disease (COPD) and
Asthma. There are a significant number of genes associated
with COPD and Asthma. The experiments evaluated the ability
of various formulations to change Asthma or COPD associated gene
expressions in human small airway epithelial cells. A
cannabis extract alone demonstrated remarkable activity in gene
arrays by up- or down-regulating individual genes by as much as
200-fold. Genes appearing especially sensitive to the
introduction of cannabis extract were associated with inflammation,
healing and cancer inhibition. Results from this series of
experiments provided a baseline for comparison with data from
subsequent studies.
In addition, KALY has entered into a joint venture agreement
named US Cannabis Health with Puration, Inc. (USOTC:
PURA), and Nouveau Pharmaceuticals, Inc. (USOTC:
NOUV) to combine their respective resources for the specific
purpose of developing partnerships with major pharmaceutical
companies to produce medical cannabis therapies.
Find out when $KALY reaches critical levels. Subscribe
to OracleDispatch.com Right Now by entering your Email in the box
below.
As noted above, KALY just announced plans to reveal a fourth
research and development initiative for the treatment of a health
issue with a cannabis extract derived from the company’s patented
cannabis extraction process. Recent action has seen 67% during the
past week in terms of shareholder gains in the listing.
What’s more, the stock has seen a growing influx of trading
interest, with the stock’s recent average trading volume running
170% above its longer-run average levels. Traders should note this
as important with the stock trading on a float that is very limited
at just shares.
According to the release, “in addition to its pharmaceutical
developments, KALY is generating revenue from its patented cannabis
extraction process delivering proprietary extracts for infusion
into non-pharmaceutical commercial products. KALY announced last
week finalizing its all-new 25 mg CBD Extract formulation for
beverage infusion. KALY’s patented extraction process already
produces a 10 mg CBD formulation for Puration, Inc.’s (USOTC:
PURA) leading EVERx CBD Sports Water. KALY has also recently
announced plans to provide commercial extraction for Nouveau, Inc.
(USOTC:
NOUV) in conjunction with NOUV’s recently announced 100-acre
hemp farm.”
Earning a current market cap value of $23.33M,
KALY has virtually no cash on the books, which
compares with about $185K in total current liabilities. KALY is
pulling in trailing 12-month revenues of $119K. In addition, the
company is seeing major top-line growth, with y/y quarterly
revenues growing at 205.1%. This is an exciting story, and we look
forward to a follow-up chapter as events
transpire. Sign-up for continuing coverage on shares
of $KALY stock, as well as other hot stock picks, get our free
newsletter today and get our next breakout pick!
Disclosure: we hold no position in $KALY, either long or
short, and we have not been compensated for this article.
Original Source: https://oracledispatch.com/2019/04/08/is-the-breakout-on-in-kali-inc-otcmktskaly/
SOURCE: James Hudson
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Apr 2023 to Apr 2024